WO2003004518A2 - Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors - Google Patents

Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors Download PDF

Info

Publication number
WO2003004518A2
WO2003004518A2 PCT/EP2002/006777 EP0206777W WO03004518A2 WO 2003004518 A2 WO2003004518 A2 WO 2003004518A2 EP 0206777 W EP0206777 W EP 0206777W WO 03004518 A2 WO03004518 A2 WO 03004518A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
lys
cys
peptide
xaa
Prior art date
Application number
PCT/EP2002/006777
Other languages
French (fr)
Other versions
WO2003004518A3 (en
Inventor
Romano Deghenghi
Original Assignee
Ardana Bioscience Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardana Bioscience Limited filed Critical Ardana Bioscience Limited
Priority to AU2002314182A priority Critical patent/AU2002314182A1/en
Publication of WO2003004518A2 publication Critical patent/WO2003004518A2/en
Publication of WO2003004518A3 publication Critical patent/WO2003004518A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to cortistatin analogs able to bind selectively to growth hormone secretagogue receptors.
  • Cortistatin (Nature, 1996, 381, 242-245) is a tetradecapeptide similar to somatostatin, but has a distinct pharmacological and physiological profile (Brain Research Reviews, 2000, 33, 228-241. Although it binds to five subtypes of somatostatin receptors (Naunyn-Schmiedeberg Arch. Pharmacol., 1998, 357,483-489), cortistatin has distinct effects on electrical cortex activity, sleep and locomotor behaviour (J. Neurosci. Res. 1999, 56, 611-619).
  • Cortistatin also bonds to growth hormone secretagogue receptors (GHS- R), unlike somatostatin (J. Endocrinol. Invest., 2001,24(1), RC1-RC3) and like ghrelin, an endogenous peptide produced in the stomach (Nature, 1999, 402, 656-660) which stimulates the production of growth hormone (J. Endocrinol. Invest., 2000, 23, 493-495), mediated by interaction with GHS-R (J. Clin. Endocrinol. Metab. 2000, 10, 3803-3807).
  • GHS- R growth hormone secretagogue receptors
  • GHS peptides can bind has been postulated.
  • Cyclic peptides have now been found which can bind selectively to the cortistatin receptor, and compete with ghrelin binding to GHS-R.
  • the peptides of the invention have the following general formula I: Pro-Cys-Xaa-D-Trp-Lys-Xbb-Cys-Lys-NH 2 I--— - I wherein:
  • Xaa represents a residue of phenylalanine (Phe), tyrosine (Tyr) or pyridyl- alanine (Pal);
  • Xbb represents a residue of threonine (Thr) or ter-leucine (Tie).
  • the invention also relates to conjugates of peptides I with metal or radioactive isotope chelating agents for radiotherapeutic or radiodiagnostic use.
  • the chelating agents can be bind to peptides I directly, via covalent bonds with one of the free functional groups present on the amino acid residues of the peptide, e.g. with the amine groups of the lysine residues, or through a bifunctional linker.
  • Suitable chelating agents which can be bonded directly or via a linker to peptides are the polyazamacrocyclic bifunctional ligands: l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid (DOTA), 1,4,7,10- tetraazacyclododecane-l,4,7-triacetic acid (D03A), [10-(2-hydroxypropyl)- l,4,7,10-tetraazacyclododecane-l,4,7-triacetic acid (HPD03A), 4-carboxy- 5,8,1 l-tris(carboxymethyl)-l-phenyl-2-oxa-5,8,l l-triazatridecan-13-oic acid (BOPTA), 2-methyl-l ,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid (MCTA), ( , ⁇ ', "
  • BMA bis amino bisthiol chelating agents
  • BAT bis amino bisthiol chelating agents
  • BSME 4-(2,2-dimethylacetyl)-benzoic acid
  • DMBA bis-succinimide- hexane
  • TSEA tris(succinimidylethyl)amine
  • Peptides I conjugated to chelating agents form stable complexes with the bi- and trivalent ions of radioactive metal isotopes ( 99m Tc, 203 Pb, 67 Ga,
  • Peptides of formula I can be used to treat disorders in which a selective interaction with the cortistatin receptor is desirable.
  • peptides I have proved useful as appetite suppressants, and can therefore be used to treat obesity, excess weight and acromegaly.
  • the radiolabelled conjugates of peptides I can be used for the treatment and/or diagnosis of tumours which express the cortistatin receptor and GH-dependent tumours such as cancer of the lung, breast, thyroid, pancreas, pituitary gland and other tissues that express GHS-R.
  • the peptides or conjugated and labelled peptides of the invention will be formulated in formulations suitable for oral, parenteral or transmucosal (sublingual, intranasal or rectal) administration.
  • suitable formulations for parenteral administration include sterile aqueous solutions or suspensions with pH values between approximately 6.0 and 8.5, and peptide concentrations ranging between 0.001 and 1.0 molar.
  • formulations may be freeze-dried and supplied as such, ready to be reconstituted at the time of use.
  • suitable formulations for oral administration include tablets and capsules, possibly gastro-protected, syrups, effervescent granules, solutions and suspensions.
  • the doses can range widely, depending on the pharmacokinetic and toxicological characteristics of the peptide chosen and the disorder in question. As a rule, the appropriate dose will be approx. 0.1 ⁇ g to 10 ⁇ g of total peptide per kg of body weight per day by the parenteral route and approx. 30 ⁇ g to approx. 1000 ⁇ g of polypeptide per kg of body weight per os in one or more administrations.
  • the dose will be determined by the dose of radioactivity required for the specific diagnostic or therapeutic application, in accordance with known parameters depending on the specific activity of the conjugate, the half-life of the radioisotope and the characteristics of the ligand.
  • the peptides of the invention can also be advantageously formulated in controlled-release compositions, for example as disclosed in EP-A-0858323.
  • the peptides of the invention can be obtained by conventional methods, for example by solid-phase peptide synthesis.
  • Solid-phase peptide synthesis starts from the C-terminal end of the peptide.
  • a suitable starting material can be prepared, for example by attaching the required protected alpha-amino acid to a chloromethylated resin, a hydroxymethylated resin, a benzhydrylamine resin (BHA), or a para- methylbenzhydrylamine resin (p-Me-BHA).
  • BHA benzhydrylamine resin
  • p-Me-BHA para- methylbenzhydrylamine resin
  • BIOBEADS SX 1 The preparation of the hydroxymethyl resin is described by Bodansky et al., Chem. Ind. (London) 38, 15997, (1966).
  • BHA resin has been described by Pietta and Marshall, Chem. Comm., 650 (1970), and is marketed by Belmont, California.
  • the alpha-amino acid protective group can be removed with a choice of acid reagents, including trifluoroacetic acid
  • each protected amino acid can generally be reacted in an excess of approximately three times using a suitable carboxyl activator group such as dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIG) in a solution of methylene chloride (CH2CI2) or dimethylformamide (DMF), and mixtures thereof, for example.
  • a suitable carboxyl activator group such as dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIG) in a solution of methylene chloride (CH2CI2) or dimethylformamide (DMF), and mixtures thereof, for example.
  • the desired peptide can be cleaved from the supporting resin by treatment with a reagent such as hydrogen fluoride (NF) which not only cleaves the peptide from the resin, but also cleaves the most common protective groups of the side chains.
  • a reagent such as hydrogen fluoride (NF) which not only cleaves the peptide from the resin, but also cleaves the most common protective groups of the side chains.
  • NF hydrogen fluoride
  • the treatment with HF gives rise to the formation of the acid peptide in free form.
  • a BHA or p-Me-BHA resin the HF treatment directly gives rise to the peptide amide in free form.
  • Pro-Cys-Tyr-D-Trp-Lys-Thr-Cys-Lys-NH 2 I - I synthesised on solid phase, has the following characteristics in acetate form:
  • Solubility 0.2 mg/ml in distilled water.
  • Solubility 0.4 mg/ml in distilled water.
  • Example 1 (Tyr -cortistatin-8) and Example 2 (cortistatin 8) to GHS-R in human pituitary gland tissue were performed by comparison with cortistatin 14, somatostatin 14 and ghrelin 28, as described in J. Endocrinol. 1998, 157, 99-106 and in J. Endocrinol. Invest., 2001, 24, RC2, using 125 I-Tyr 4 -ghrelin as ligand.
  • the results are shown in the annexed Figures la-c.
  • the IC 50 calculated for the peptides of the invention ranged between 24 and 33 nM, those of ghrelin-28 between 7.5 and 9.5, and those of cortistatin 14 between 11.6 and 14, while those of somatostatin always exceeded 1000 nM.
  • the peptide described in example 2 was administered subcutaneously at the dose of 300 meg/Kg to Sprague-Dawley rats weighing approx. 200-250 g, whose appetite was stimulated by subcutaneous injection with 80 meg/Kg of the peptide GHS Hexarelin.
  • the animals were also treated in accordance with a crossover protocol with Hexarelin only or with saline, and their food consumption was recorded hourly for the six hours following the treatment, as described in European J. Endocrinol., 2001, 144, 155-162.
  • Total food consumption was 0.86 + 0.28 g for the treatment with saline, 0.85 + 0.19 g for the treatment with Hexarelin associated with the peptide described in Example 2, and 3.33 + 0.47 g for the treatment with Hexarelin only.

Abstract

The peptides of formula (I): Pro-Cys-Xaa-D-Trp-Lys-Xbb-Cys-Lys-NH2, and their derivatives with metal chelating agents are useful in the treatment of tumours and acromegaly, and to reduce the appetite.

Description

CORTISTATIN ANALOGS CAPABLE OF BINDING SELECTIVELY TO GROWTH HORMONE SECRETAGOGUE RECEPTORS
The present invention relates to cortistatin analogs able to bind selectively to growth hormone secretagogue receptors.
Cortistatin (Nature, 1996, 381, 242-245) is a tetradecapeptide similar to somatostatin, but has a distinct pharmacological and physiological profile (Brain Research Reviews, 2000, 33, 228-241. Although it binds to five subtypes of somatostatin receptors (Naunyn-Schmiedeberg Arch. Pharmacol., 1998, 357,483-489), cortistatin has distinct effects on electrical cortex activity, sleep and locomotor behaviour (J. Neurosci. Res. 1999, 56, 611-619).
Cortistatin also bonds to growth hormone secretagogue receptors (GHS- R), unlike somatostatin (J. Endocrinol. Invest., 2001,24(1), RC1-RC3) and like ghrelin, an endogenous peptide produced in the stomach (Nature, 1999, 402, 656-660) which stimulates the production of growth hormone (J. Endocrinol. Invest., 2000, 23, 493-495), mediated by interaction with GHS-R (J. Clin. Endocrinol. Metab. 2000, 10, 3803-3807). The existence of specific corticϋstatin receptors to which the synthetic
GHS peptides can bind has been postulated.
Cyclic peptides have now been found which can bind selectively to the cortistatin receptor, and compete with ghrelin binding to GHS-R.
The peptides of the invention have the following general formula I: Pro-Cys-Xaa-D-Trp-Lys-Xbb-Cys-Lys-NH2 I--— - I wherein:
Xaa represents a residue of phenylalanine (Phe), tyrosine (Tyr) or pyridyl- alanine (Pal); Xbb represents a residue of threonine (Thr) or ter-leucine (Tie). The invention also relates to conjugates of peptides I with metal or radioactive isotope chelating agents for radiotherapeutic or radiodiagnostic use. The chelating agents can be bind to peptides I directly, via covalent bonds with one of the free functional groups present on the amino acid residues of the peptide, e.g. with the amine groups of the lysine residues, or through a bifunctional linker.
Examples of suitable chelating agents which can be bonded directly or via a linker to peptides are the polyazamacrocyclic bifunctional ligands: l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid (DOTA), 1,4,7,10- tetraazacyclododecane-l,4,7-triacetic acid (D03A), [10-(2-hydroxypropyl)- l,4,7,10-tetraazacyclododecane-l,4,7-triacetic acid (HPD03A), 4-carboxy- 5,8,1 l-tris(carboxymethyl)-l-phenyl-2-oxa-5,8,l l-triazatridecan-13-oic acid (BOPTA), 2-methyl-l ,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid (MCTA), ( ,α', ",α"')-tetramethyl-l ,4,7, 10-tetraazacyclododecane- 1 ,4,7, 10- tetracetic acid (DOTMA); the residue of polyaminophosphates, in particular N,N'-bis-(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid (DPDP) and ethyl enedinitrilotetrakis(methylphosphonic) acid (EDTP); residues of polyaminophosphonic or polyaminophosphinic acids, in particular 1,4,7,10- tetraazacyclododecane- 1 ,4,7, 10-tetrakis[methylene(methylphosphonic)] acid and l,4,7,10-tetraazacyclododecane-l,4,7, 10-tetrakis[methylene (methyl- phosphonic)] acid; the residue of natural macrocyclic chelating agents such as texaphyrines, porphyrines and phthalocyanines; diethylenetriaminepentaacetic acid (DTP A) and its derivatives such as N,N-bis[2-[bis(carboxymethyl)- amino]ethyl]L-glutamic acid (DTPA-GLU), DTP A conjugated with Lys (DTPA-Lys), N-[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-N- [2-[bis(carboxymethyl)amino]ethylglycme (EOB-DTPA), N,N-bis[2-
[(carboxymethyl) [(methylcarb amoyl)methyl] amino] ethyl] glycine (DTP A-
BMA); N3S triamidothiols, N2S2 diamidodithiols, N4 tetramines, 2-hydrazine-nicotinic acid, and bis amino bisthiol chelating agents (BAT). The structural formulas of these known chelating agents and conjugation and radiolabelling techniques are described in Current Medicinal Chemistry, 2000, 7, 871-994, the contents of which are incorporated here by reference. Suitable bifunctional linkers include bis-succinimidylmethyl ether
(BSME), 4-(2,2-dimethylacetyl)-benzoic acid (DMBA), bis-succinimide- hexane (BSH), tris(succinimidylethyl)amine (TSEA), and similar derivatives having succinimide, thio, carboxy or amine groups.
Peptides I conjugated to chelating agents form stable complexes with the bi- and trivalent ions of radioactive metal isotopes (99mTc, 203Pb, 67Ga,
68Ga, 72As, n ιIn, 113In, 90Yt, 97Ru, 82mRb, 62Cu, 64Cu, 52Fe, 52mMn, 140La, 175Yb,
153Sm, 166Ho, 149Pm, 177Lu, 142Pr, 159Gd, 212Bi, 47Sc, 149Pm, 67Cu, mAg, 199Au,
188Re, 186Re, 161Tb and 51Cr), which complexes are also part of the invention.
Peptides of formula I can be used to treat disorders in which a selective interaction with the cortistatin receptor is desirable. In particular, peptides I have proved useful as appetite suppressants, and can therefore be used to treat obesity, excess weight and acromegaly. The radiolabelled conjugates of peptides I can be used for the treatment and/or diagnosis of tumours which express the cortistatin receptor and GH-dependent tumours such as cancer of the lung, breast, thyroid, pancreas, pituitary gland and other tissues that express GHS-R.
For the proposed therapeutic and diagnostic uses, the peptides or conjugated and labelled peptides of the invention will be formulated in formulations suitable for oral, parenteral or transmucosal (sublingual, intranasal or rectal) administration.
Examples of suitable formulations for parenteral administration include sterile aqueous solutions or suspensions with pH values between approximately 6.0 and 8.5, and peptide concentrations ranging between 0.001 and 1.0 molar.
These formulations may be freeze-dried and supplied as such, ready to be reconstituted at the time of use.
Examples of suitable formulations for oral administration include tablets and capsules, possibly gastro-protected, syrups, effervescent granules, solutions and suspensions.
The doses can range widely, depending on the pharmacokinetic and toxicological characteristics of the peptide chosen and the disorder in question. As a rule, the appropriate dose will be approx. 0.1 μg to 10 μg of total peptide per kg of body weight per day by the parenteral route and approx. 30 μg to approx. 1000 μg of polypeptide per kg of body weight per os in one or more administrations. In the case of radiolabelled peptides, the dose will be determined by the dose of radioactivity required for the specific diagnostic or therapeutic application, in accordance with known parameters depending on the specific activity of the conjugate, the half-life of the radioisotope and the characteristics of the ligand.
The peptides of the invention can also be advantageously formulated in controlled-release compositions, for example as disclosed in EP-A-0858323. The peptides of the invention can be obtained by conventional methods, for example by solid-phase peptide synthesis.
Solid-phase peptide synthesis starts from the C-terminal end of the peptide. A suitable starting material can be prepared, for example by attaching the required protected alpha-amino acid to a chloromethylated resin, a hydroxymethylated resin, a benzhydrylamine resin (BHA), or a para- methylbenzhydrylamine resin (p-Me-BHA). One of these chloromethylated resins is manufactured by BioRad Laboratories, Richmond, California, and sold under the trademark BIOBEADS SX 1. The preparation of the hydroxymethyl resin is described by Bodansky et al., Chem. Ind. (London) 38, 15997, (1966). BHA resin has been described by Pietta and Marshall, Chem. Comm., 650 (1970), and is marketed by Peninsula Laboratories Inc., Belmont, California.
After the initial attachment, the alpha-amino acid protective group can be removed with a choice of acid reagents, including trifluoroacetic acid
(TFA) or hydrochloric acid (HC1) in a solution of organic solvents at room temperature. After removal of the alpha-amino acid protective group, the remaining protected amino acids can be coupled step by step in the desired order. Each protected amino acid can generally be reacted in an excess of approximately three times using a suitable carboxyl activator group such as dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIG) in a solution of methylene chloride (CH2CI2) or dimethylformamide (DMF), and mixtures thereof, for example. When the desired amino acid sequence has been completed, the desired peptide can be cleaved from the supporting resin by treatment with a reagent such as hydrogen fluoride (NF) which not only cleaves the peptide from the resin, but also cleaves the most common protective groups of the side chains. When a chloromethylated or hydroxymethylated resin is used, the treatment with HF gives rise to the formation of the acid peptide in free form. When a BHA or p-Me-BHA resin is used, the HF treatment directly gives rise to the peptide amide in free form.
The solid-phase procedure discussed above is known to the prior art, and was described by Atherton and Sheppard, Solid Phase Peptide Synthesis (IRL Press, Oxford, 1989).
Some methods in solution, which can be used to synthesise the peptide portions of this invention, are specified in Bodansky et al., Peptide Synthesis, 2nd edition, John Wiley & Sons, New York, N.Y. 1976, and by Jones, The Chemical Synthesis of Peptides, (Clarendon Press, Oxford, 1994).
The following examples illustrate the invention in greater detail. EXAMPLE 1
The peptide of formula:
Pro-Cys-Tyr-D-Trp-Lys-Thr-Cys-Lys-NH2 I - I synthesised on solid phase, has the following characteristics in acetate form:
Mass spectrum: M+ 1025.3
Solubility: 0.2 mg/ml in distilled water.
HPLC titre: 99%
Amino acid analysis: conforming. EXAMPLE 2
The peptide of formula:
Pro-Cys-Phe-D-Trp-Lys-Thr-Cys-Lys-NH2 I- ~I synthesised on solid phase, has the following characteristics in acetate form: Mass spectrum: M+ 1009.2
Solubility: 0.4 mg/ml in distilled water.
HPLC titre: 95%
Amino acid analysis: conforming.
EXAMPLE 3 - Binding studies The studies carried out on the binding of the peptide described in
Example 1 (Tyr -cortistatin-8) and Example 2 (cortistatin 8) to GHS-R in human pituitary gland tissue were performed by comparison with cortistatin 14, somatostatin 14 and ghrelin 28, as described in J. Endocrinol. 1998, 157, 99-106 and in J. Endocrinol. Invest., 2001, 24, RC2, using 125I-Tyr4-ghrelin as ligand.
The results are shown in the annexed Figures la-c. The IC50 calculated for the peptides of the invention ranged between 24 and 33 nM, those of ghrelin-28 between 7.5 and 9.5, and those of cortistatin 14 between 11.6 and 14, while those of somatostatin always exceeded 1000 nM.
EXAMPLE 4 - Effect on food consumption.
The peptide described in example 2 was administered subcutaneously at the dose of 300 meg/Kg to Sprague-Dawley rats weighing approx. 200-250 g, whose appetite was stimulated by subcutaneous injection with 80 meg/Kg of the peptide GHS Hexarelin.
The animals were also treated in accordance with a crossover protocol with Hexarelin only or with saline, and their food consumption was recorded hourly for the six hours following the treatment, as described in European J. Endocrinol., 2001, 144, 155-162.
Total food consumption was 0.86 + 0.28 g for the treatment with saline, 0.85 + 0.19 g for the treatment with Hexarelin associated with the peptide described in Example 2, and 3.33 + 0.47 g for the treatment with Hexarelin only.

Claims

1. Peptides of formula I
Pro-Cys-Xaa-D-Trp-Lys-Xbb-Cys-Lys-NH2 I I
I wherein
Xaa represents a residue of phenylalanine (Phe), tyrosine (Tyr) or pyridyl- alanine (Pal); Xbb represents a residue of threonine (Thr) or ter-leucine (Tie).
2. Peptides as claimed in claim 1, wherein Xaa is Tyr.
3. Peptides as claimed in claim 1, wherein Xaa is Phe.
4. Peptides as claimed in claim 1, wherein Xbb is Thr.
5. A peptide as claimed in claim 1, selected from: Pro-Cys-Phe-D-Trp-Lys-Thr-Cys-Lys-NH2 I -I
Pro-Cys-Tyr-D-Trp-Lys-Thr-Cys-Lys-NH2 I I
6. Conjugates of the peptides as claimed in claims 1-5 with metal or radioactive isotope chelating agents, and the corresponding chelated complexes of the said metals or isotopes.
7. Conjugates as claimed in claim 6, wherein peptides I are bonded to the chelating agent directly via covalent bonds with one of the free functional groups present on the amino acid residues of the peptide, or via a bifunctional linker.
8. Chelated complexes as claimed in claim 6 or 7 of metals selected from 99mTc, 203Pb, 67Ga, 68Ga, 72As, mIn, 113In, 90Yt, 97Ru, 82mRb, 62Cu, 64Cu, 52Fe, 52mMn, 140La, 175Yb, 153Sm, 166Ho, 149Pm, 177Lu, 142Pr, 159Gd, 212Bi, 47Sc, 149Pm, 67Cu, mAg, 199Au, 188Re, 186Re, 161Tb and 51Cr.
9. Pharmaceutical or diagnostic compositions containing one of the peptides as claimed in claims 1-5 or one of the chelated complexes as claimed in claims 6-8, mixed with a suitable vehicle.
10. Pharmaceutical compositions as claimed in claim 9, with controlled release.
11. Use of the peptides as claimed in claims 1-5 or the chelated complexes as claimed in claims 6-8 for the preparation of medicaments for the treatment of tumours and acromegaly and to reduce the appetite.
PCT/EP2002/006777 2001-07-06 2002-06-19 Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors WO2003004518A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002314182A AU2002314182A1 (en) 2001-07-06 2002-06-19 Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI01A001445 2001-07-06
IT2001MI001445A ITMI20011445A1 (en) 2001-07-06 2001-07-06 ANALOGUES OF CORTISTANTINA CAPABLE OF BINDING SELECTIVELY TO THE RECEPTORS OF SECRETAGOGUES OF GROWTH HORMONE

Publications (2)

Publication Number Publication Date
WO2003004518A2 true WO2003004518A2 (en) 2003-01-16
WO2003004518A3 WO2003004518A3 (en) 2003-04-10

Family

ID=11448017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006777 WO2003004518A2 (en) 2001-07-06 2002-06-19 Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors

Country Status (3)

Country Link
AU (1) AU2002314182A1 (en)
IT (1) ITMI20011445A1 (en)
WO (1) WO2003004518A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098716A1 (en) 2006-02-28 2007-09-07 Centro De Ingeniería Genética Y Biotecnología Compounds analogous to growth hormone peptide secretagogues and preparations containing them
WO2011053821A1 (en) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
EP2457893A1 (en) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Intermediates for macrocyclic modulators of the ghrelin receptor
EP2644618A1 (en) 2007-02-09 2013-10-02 Tranzyme Pharma, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
US9714255B2 (en) 2008-08-28 2017-07-25 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
US9994582B2 (en) 2013-12-24 2018-06-12 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US10273240B2 (en) 2015-05-08 2019-04-30 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
US10273264B2 (en) 2015-07-01 2019-04-30 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 2001 (2001-01) DEGHENGHI R ET AL: "Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland." Database accession no. PREV200100128359 XP002224725 & JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, vol. 24, no. 1, January 2001 (2001-01), pages RC1-RC3, ISSN: 0391-4097 *
PAPOTTI MAURO ET AL: "Growth hormone secretagogue binding sites in peripheral human tissues." JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 85, no. 10, October 2000 (2000-10), pages 3803-3807, XP002224724 ISSN: 0021-972X *
SPIER AVRON D ET AL: "Cortistatin: A member of the somatostatin neuropeptide family with distinct physiological functions." BRAIN RESEARCH REVIEWS, vol. 33, no. 2-3, September 2000 (2000-09), pages 228-241, XP002224723 ISSN: 0165-0173 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457893A1 (en) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Intermediates for macrocyclic modulators of the ghrelin receptor
EP2457925A1 (en) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Process for preparing a macrocyclic modulator of the ghrelin receptor and intermediates
WO2007098716A1 (en) 2006-02-28 2007-09-07 Centro De Ingeniería Genética Y Biotecnología Compounds analogous to growth hormone peptide secretagogues and preparations containing them
EP2644618A1 (en) 2007-02-09 2013-10-02 Tranzyme Pharma, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
US9714255B2 (en) 2008-08-28 2017-07-25 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
US10202400B2 (en) 2008-08-28 2019-02-12 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
WO2011053821A1 (en) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US9994582B2 (en) 2013-12-24 2018-06-12 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US10273241B2 (en) 2013-12-24 2019-04-30 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US10508121B2 (en) 2013-12-24 2019-12-17 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US10273240B2 (en) 2015-05-08 2019-04-30 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
US10273264B2 (en) 2015-07-01 2019-04-30 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof

Also Published As

Publication number Publication date
AU2002314182A1 (en) 2003-01-21
ITMI20011445A0 (en) 2001-07-06
ITMI20011445A1 (en) 2003-01-06
WO2003004518A3 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
AU638043B2 (en) Labeled polypeptide derivatives
AU2004259028C1 (en) Stable radiopharmaceutical compositions and methods for preparation
AU690071B2 (en) Radioactively-labeled somatostantin-derived peptides for imaging and therapeutic uses
US5723577A (en) Analogs of parathyroid hormone
JP3647881B2 (en) Analogue compounds of radioactive metal element binding peptides
ES2274517T3 (en) CONJUGADOS DE PEPTIDO-QUELATO METALICO THAT JOIN THE SOMATOSTATIN.
AU701083B2 (en) Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses
ES2258286T3 (en) PTHRP ANALOGS
IL92534A (en) Somatostatinpeptide derivatives containing chelating groups, their preparation and pharmaceutical compositions containing them
US5969095A (en) Analogs of parathyroid hormone
JPH09501419A (en) Somatostatin derivatives and their radiolabels
EP1872800B1 (en) Radiolabeled peptide compositions for site-specific targeting
US20030198598A1 (en) Polypeptide derivatives
ES2305000T3 (en) SOMATOSTATINE ANALOGS, RADIOMARCED DERIVATIVES AND ITS USE.
WO2003004518A2 (en) Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors
JP2005503350A (en) Preparation of cholecystokinin agonists and antagonists and their therapeutic and diagnostic uses
US5871711A (en) Radioactively-labeled somatostatin-derived peptides for imaging and therapeutic uses
EP0741747A1 (en) Inhibitors of serine proteases, bearing a chelating group
EP0885017A2 (en) Use of labelled cck-b receptor ligands for the detection and localization of malignant human tumours
AU1828801A (en) Radioactively-labeled somatostantin-derived peptides for imaging and therapeutic uses
PL191239B1 (en) Analog of parathyroid hormone peptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002740736

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002740736

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP